Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in H1-antihistamine–refractory chronic spontaneous urticaria
CTR20200579Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in chronic idiopathic urticaria (CIU), sponsored by Sanofi. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20200579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200579.